

# Sara Gamba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9800683/publications.pdf>

Version: 2024-02-01

13  
papers

2,826  
citations

840776

11  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

2304  
citing authors

#	ARTICLE	IF	CITATIONS
1	Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1844-1859.	4.5	818
2	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. <i>Blood</i> , 2006, 108, 1267-1279.	1.4	652
3	Familial haemolytic uraemic syndrome and an MCP mutation. <i>Lancet, The</i> , 2003, 362, 1542-1547.	13.7	303
4	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. <i>Human Molecular Genetics</i> , 2003, 12, 3385-3395.	2.9	291
5	Interleukin-6 and RANTES in Takayasu Arteritis. <i>Circulation</i> , 1999, 100, 55-60.	1.6	216
6	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. <i>Blood</i> , 2002, 100, 778-785.	1.4	200
7	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. <i>Molecular Immunology</i> , 2016, 71, 131-142.	2.2	126
8	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 283-294.	6.1	89
9	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 224-238.	1.9	45
10	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. <i>PLoS Medicine</i> , 2019, 16, e1002777.	8.4	42
11	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. <i>Blood Advances</i> , 2022, 6, 866-881.	5.2	31
12	A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study. <i>Nephron</i> , 2015, 130, 13-20.	1.8	9
13	Direct medical costs of monitoring and treating patients with Takayasu arteritis in Italy. <i>European Journal of Health Economics</i> , 2004, 5, 330-334.	2.8	4